Literature DB >> 29462007

Risk Factors for Recurrence After Treatment of N1b Papillary Thyroid Carcinoma.

Sang Hun Lee1, Jong-Lyel Roh1, Gyungyup Gong2, Kyung-Ja Cho2, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim1.   

Abstract

OBJECTIVES: To examine risk factors for posttreatment recurrence in papillary thyroid carcinoma (PTC) patients with initial presentation of lateral neck metastasis (N1b). SUMMARY OF BACKGROUND DATA: N1b PTC recurs after definitive treatment.
METHODS: Study subjects were 437 consecutive PTC patients who underwent total thyroidectomy and therapeutic neck dissection of central and lateral compartments and postoperative radioactive iodine ablation therapy. The patients' demographics and pathological factors, including factors related to tumors and lymph nodes (LNs), and postoperative thyroglobulin levels were reviewed. Univariate and multivariate Cox proportional hazards regression analyses were used to identify factors associated with recurrence-free survival (RFS).
RESULTS: During a median follow-up of 83 months (range, 32-135 months), recurrence occurred in 81 (18.1%) patients. Univariate analyses showed that male sex, tumor size, macroscopic extrathyroidal extension, perineural invasion, extranodal extension, LN involvement, LN ratio, MACIS score, and postoperative serum levels of thyroglobulin were significantly associated with RFS (P < 0.05). Multivariate analyses revealed that LN ratio (> 0.25) in the lateral compartment (adjusted hazard ratio = 2.099, 95% confidence interval = 1.278-3.448; P = 0.003), and postoperative serum levels of stimulated (>5.0 ng/mL; 3.172, 1.661-6.056, P < 0.001) and unstimulated (>0.1 ng/mL; 3.200, 1.569-6.526, P = 0.001) thyroglobulin were independent predictors of any-site RFS. Clinical and tumor factors were not independent predictors of RFS outcomes (P > 0.1).
CONCLUSIONS: Posttreatment recurrence is predicted by the LN ratio in the lateral compartment and postoperative serum levels of thyroglobulin in patients with metastatic PTC in the lateral neck.

Entities:  

Year:  2019        PMID: 29462007     DOI: 10.1097/SLA.0000000000002710

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  16 in total

1.  Long noncoding RNA SNHG6 promotes papillary thyroid cancer cells proliferation via regulating miR-186/CDK6 axis.

Authors:  Jian Xu; Miaomiao Liao
Journal:  Gland Surg       Date:  2021-10

2.  MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.

Authors:  Congjun Wang; Ye Wang; Zhao Fu; Weijia Huang; Zhu Yu; Jiancheng Wang; Kaitian Zheng; Siwen Zhang; Shen Li; Junqiang Chen
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

3.  Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.

Authors:  Chunyan Zhou; Dong Duan; Shuang Liu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

4.  Preoperative Nodal US Features for Predicting Recurrence in N1b Papillary Thyroid Carcinoma.

Authors:  Na Lae Eun; Jeong-Ah Kim; Hye Mi Gweon; Ji Hyun Youk; Eun Ju Son
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

5.  Association of the Preoperative Inflammation-Based Scores with TNM Stage and Recurrence in Patients with Papillary Thyroid Carcinoma: A Retrospective, Multicenter Analysis.

Authors:  Wenjie Chen; Tao Wei; Zhihui Li; Rixiang Gong; Jianyong Lei; Jingqiang Zhu; Tao Huang
Journal:  Cancer Manag Res       Date:  2020-03-11       Impact factor: 3.989

6.  The correlation between ultrasonographic features, bFGF, and the local invasiveness of thyroid papillary carcinoma.

Authors:  Zhi-Ying Jia; Xiu-Lan Wu; Yin-Hua Zhang; Bin-Lin Ma; Fu-Cheng Ma
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

7.  Preoperative serum thyroglobulin is a risk factor of skip metastasis in papillary thyroid carcinoma.

Authors:  Ziyang Huang; Muye Song; Shujie Wang; Jianhao Huang; Hongyan Shi; Yijie Huang; Ying Yin; Yongchen Liu; Zeyu Wu
Journal:  Ann Transl Med       Date:  2020-03

8.  Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.

Authors:  Meihua Jin; Jonghwa Ahn; Yu-Mi Lee; Tae-Yon Sung; Won Gu Kim; Tae Yong Kim; Jin-Sook Ryu; Won Bae Kim; Young Kee Shong; Min Ji Jeon
Journal:  Endocrinol Metab (Seoul)       Date:  2020-09-22

9.  Predictive Factors for Skip Lymph Node Metastasis and Their Implication on Recurrence in Papillary Thyroid Carcinoma.

Authors:  Young-Jae Ryu; Seong-Young Kwon; Soo-Young Lim; Yong-Min Na; Min-Ho Park
Journal:  Biomedicines       Date:  2022-01-16

10.  Unilateral papillary thyroid carcinoma treated with contralateral central lymph node dissection: A nomogram to aid in decision-making.

Authors:  Wenjie Chen; Zhihui Li; Jingqiang Zhu; Jianyong Lei; Tao Wei
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.